Last reviewed · How we verify
Indolent B-Cell Lymphoma
Approved treatments
- Treanda · Baxter
Treanda works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow. - Bendamustin · Meir Medical Center
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Indolent B-Cell Lymphoma patent landscape — cliff calendar, originator estates, attackable patents
- Indolent B-Cell Lymphoma treatment landscape brief
- Indolent B-Cell Lymphoma treatment updates RSS
Frequently asked questions about Indolent B-Cell Lymphoma
What drugs treat Indolent B-Cell Lymphoma?
Tracked treatments include Treanda, Bendamustin.
What is the treatment for Indolent B-Cell Lymphoma?
Standard treatment for Indolent B-Cell Lymphoma includes Treanda, Bendamustin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Indolent B-Cell Lymphoma patent cliff · Indolent B-Cell Lymphoma CI report
- Treatment: Treanda · Baxter
- Treatment: Bendamustin · Meir Medical Center
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing